Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year

Konskie,,Poland,-,June,09,,2024:,Rapport,Therapeutics,Inc,Company

Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro.

On Monday, the company revealed data from the Phase 2a trial of RAP-219 (RAP-219-FOS-201) in patients with drug-resistant focal onset seizures.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.